Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fluzoparib + SHR-A1811
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Oral, Intravenous
01
Overview
fluzoparib + SHR-A1811 is an investigational combination therapy being developed by Jiangsu Hengrui Pharmaceuticals for the treatment of HER2-expressing or HER2-mutated solid tumors. Fluzoparib is a potent, orally bioavailable small molecule inhibitor of poly (ADP-ribose) polymerase 1 (PARP1) and PARP2, which prevents DNA damage repair and induces synthetic lethality in cancer cells. SHR-A1811 is a next-generation antibody-drug conjugate (ADC) consisting of a humanized anti-HER2 monoclonal antibody conjugated to a topoisomerase I inhibitor payload (SHR152852) via a cleavable linker. The combination therapy is designed to enhance anti-tumor activity by combining the DNA-damaging effects of the ADC's payload with the DNA repair inhibition of the PARP inhibitor, potentially overcoming resistance and improving outcomes in patients with HER2-positive malignancies.
- Brand names
- fluzoparib
- Other names
- SHR-A1811SHR-A-1811SHR-A 1811FuzuloparibHS-10160HS10160HS 10160SHR 3162SHR3162SHR-3162
02
Targets
TOP1 (DNA Topoisomerase I)PARP2 (Poly (adp-ribose) polymerase 2)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on fluzoparib + SHR-A1811.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fluzoparib + SHR-A1811.